The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Gilead HIV Drug as Effective as Merck's in Trial

March 25, 2011

Gilead Sciences Inc. this week reported late-stage clinical trial results showing that its experimental once-daily HIV drug elvitegravir proved as effective as Merck & Co.'s twice-daily drug Isentress (raltegravir). In the study, patients were given an antiretroviral regimen plus elvitegravir or Isentress. After 48 weeks, 59 percent of the elvitegravir patients had achieved the targeted viral load levels, versus 57.8 percent of the Isentress group. Discontinuation rates due to adverse events were comparable in both groups. Gilead plans to submit the presentation data later this year at a scientific conference. Elvitegravir is designed to thwart HIV's ability to invade human cells' genetic material.

Back to other news for March 2011

Adapted from:
03.23.2011; Toni Clark

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
More on HIV Medications
HIV Drugs in Development

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: